


PHARMACEUTICAL 2019

MARIZYME INC Rank 20 of 371







PHARMACEUTICAL 2019





The relative strengths and weaknesses of MARIZYME INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 253% points. The greatest weakness of MARIZYME INC is the variable Revenues, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 212%, being 544% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	20
Cost of Goods Sold	20
Intangible Assets	28,600
Liabilities, Current	43
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	234
Other Liabilities	0
Other Net Income	-1.6
Property and Equipment	0
Research and Development	0
Revenues	20
Selling, General and Administrative Expense	13

Output Variable	Value in 1000 USD
Assets	28,620
Liabilities	43
Expenses	267
Stockholders Equity	28,577
Net Income	-249
Comprehensive Net Income	-249
Economic Capital Ratio	212%